RASSF1A promoter methylation levels positively correlate with estrogen receptor expression in breast cancer patients

Translational Oncology

Volumn 6, Issue 3, 2013, Pages 297-304

  Kajabova, Viera ^a   Smolkova, Bozena ^a   Zmetakova, Iveta ^a   Sebova, Katarina ^a   Krivulcik, Tomas ^a   Bella, Vladimir ^b   Kajo, Karol ^b   Machalekova, Katarina ^b   Fridrichova, Ivana ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b ST ELIZABETH CANCER INSTITUTE   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN KINASE SYK; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UVOMORULIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER STAGING; CONTROLLED STUDY; DISTANT METASTASIS; DNA METHYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTIPLEX POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 84878741904     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.13244     Document Type: Article

References (37)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM (2008). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917.
2. Barinoff J, Hils R, Bender A, Groß J, Kurz C, Tauchert S, Mann E, Schwidde I, Ipsen B, Sawitzki K, et al. (2012). Clinicopathological differences between breast cancer in patients with primary metastatic disease and those without: a multicentre study. Eur J Cancer 49, 305-311.
3. Clark GM, Sledge GW Jr, Osborne CK, and McGuire WL (1987). Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5, 55-61.
4. Jones PA and Baylin SB (2002). The fundamental role of epigenetic events in cancer. Nat Rev Genet 3, 415-428.
5. Dammann R, Schagdarsurengin U, Seidel C, Strunnikova M, Rastetter M, Baier K, and Pfeifer GP (2005). The tumor suppressor RASSF1A in human carcinogenesis: an update. Histol Histopathol 20, 645-663.
6. Feng W, Orlandi R, Zhao N, Carcangiu ML, Tagliabue E, Xu J, Bast RC Jr, and Yu Y (2010). Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers. BMC Cancer 10, 378.
7. Pasquali L, Bedeir A, Ringquist S, Styche A, Bhargava R, and Trucco G (2007). Quantification of CpG island methylation in progressive breast lesions from normal to invasive carcinoma. Cancer Lett 257, 136-144.
8. Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, and Hoon DS (2008). Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors. Breast Cancer Res 10, 46.
9. Feng W, Shen L, Wen S, Rosen DG, Jelinek J, Hu X, Huan S, Huang M, Liu J, Sahin AA, et al. (2007). Correlation between CpG methylation profiles and hormone receptor status in breast cancers. Breast Cancer Res 9, 57.
10. Thaler S, Schmidt M, Schad A, and Sleeman JP (2012). RASSF1A inhibits estrogen receptor alpha expression and estrogen-independent signalling: implications for breast cancer development. Oncogene 31, 4912-4922.
11. Gaudet MM, Campan M, Figueroa JD, Yang XR, Lissowska J, Peplonska B, Brinton LA, Rimm DL, Laird PW, Garcia-Closas M, et al. (2009). DNA hypermethylation of ESR1 and PGR in breast cancer: pathologic and epidemiologic associations. Cancer Epidemiol Biomarkers Prev 18, 3036-3043.
12. Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, and Laird PW (2004). Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 64, 3807-3813.
13. Graff JR, Gabrielson E, Fujii H, Baylin SB, and Herman JG (2000). Methylation patterns of the E-cadherin 5′ CpG island are unstable and reflect the dynamic, heterogeneous loss of E-cadherin expression during metastatic progression. J Biol Chem 275, 2727-2732.
14. Caldeira JR, Prando EC, Quevedo FC, Neto FA, Rainho CA, and Rogatto SR (2006). CDH1 promoter hypermethylation and E-cadherin protein expression in infiltrating breast cancer. BMC Cancer 6, 48.
15. Bachman KE, Herman JG, Corn PG, Merlo A, Costello JF, Cavenee WK, Baylin SB, and Graff JR (1999). Methylation-associated silencing of the tissue inhibitor of metalloproteinase-3 gene suggest a suppressor role in kidney, brain, and other human cancers. Cancer Res 59, 798-802.
16. Lui EL, Loo WT, Zhu L, Cheung MN, and Chow LW (2005). DNA hypermethylation of TIMP3 gene in invasive breast ductal carcinoma. Biomed Pharmacother 59, 363-365.
17. Coopman PJ and Mueller SC (2006). The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett 241, 159-173.
18. Yuan Y, Liu H, Sahin A, and Dai JL (2005). Reactivation of SYK expression by inhibition of DNA methylation suppresses breast cancer cell invasiveness. Int J Cancer 113, 654-659.
19. Swift-Scanlan T, Blackford A, Argani P, Sukumar S, and Fackler MJ (2006). Two-color quantitative multiplex methylation-specific PCR. Biotechniques 40, 210-219.
20. Sebova K, Zmetakova I, Bella V, Kajo K, Stankovicova I, Kajabova V, Krivulcik T, Lasabova Z, Tomka M, Galbavy S, et al. (2011-2012). RASSF1A and CDH1 hypermethylation as potential epimarkers in breast cancer. Cancer Biomark 10, 13-26.
21. Fackler MJ, McVeigh M, Mehrotra J, Blum MA, Lange J, Lapides A, Garrett E, Argani P, and Sukumar S (2004). Quantitative multiplex methylation-specific PCR assay for the detection of promoter hypermethylation in multiple genes in breast cancer. Cancer Res 64, 4442-4452.
22. Cho YH, Yazici H, Wu HC, Terry MB, Gonzalez K, Qu M, Dalay N, and Santella RM (2010). Aberrant promoter hypermethylation and genomic hypomethylation in tumor, adjacent normal tissues and blood from breast cancer patients. Anticancer Res 30, 2489-2496.
23. Buhmeida A, Merdad A, Al-Maghrabi J, Al-Thobaiti F, Ata M, Bugis A, Syrjänen K, Abuzenadah A, Chaudhary A, Gari M, et al. (2011). RASSF1A methylation is predictive of poor prognosis in female breast cancer in a background of overall low methylation frequency. Anticancer Res 31, 2975-2981.
24. Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, Gonzalez K, Xu X, Bradshaw PT, Teitelbaum SL, Garbowski G, et al. (2012). Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat 131, 197-205.
25. Gagnon JF, Sanschagrin F, Jacob S, Tremblay AA, Provencher L, Robert J, Morin C, and Diorio C (2010). Quantitative DNA methylation analysis of laser capture microdissected formalin-fixed and paraffin-embedded tissues. Exp Mol Pathol 88, 184-189.
26. Kim JH, Shin MH, Kweon SS, Park MH, Yoon JH, Lee JS, Choi C, Fackler MJ, and Sukumar S (2010). Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women. Gynecol Oncol 118, 176-181.
27. Zurita M, Lara PC, del Moral R, Torres B, Linares-Fernández JL, Arrabal SR, Martínez-Galán J, Oliver FJ, and Ruiz de Almodóvar JM (2010). Hypermethylated 14-3-3-σ and ESR1 gene promoters in serum as candidate biomarkers for the diagnosis and treatment efficacy of breast cancer metastasis. BMC Cancer 10, 217.
28. Jahr S, Hentze H, Englisch S, Hardt D, Fackelmayer FO, Hesch RD, and Knippers R (2001). DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. Cancer Res 61, 1659-1665.
29. Jung K, Fleischhacker M, and Rabien A (2010). Cell-free DNA in the blood as a solid tumor biomarker-a critical appraisal of the literature. Clin Chim Acta 411, 1611-1624.
30. Park SY, Kwon HJ, Lee HE, Ryu HS, Kim SW, Kim JH, Kim IA, Jung N, Cho NY, and Kang GH (2011). Promoter CpG island hypermethylation during breast cancer progression. Virchows Arch 458, 73-84.
31. Khan SA, Yee KA, Kaplan C, and Siddiqui JF (2002). Estrogen receptor α expression in normal human breast epithelium is consistent over time. Int J Cancer 102, 334-337.
32. Khan SA, Rogers MA, Khurana KK, Meguid MM, and Numann PJ (1998). Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90, 37-42.
33. Woolcott CG, SenGupta SK, Hanna WM, and Aronson KJ (2008). Estrogen and progesterone receptor levels in nonneoplastic breast epithelium of breast cancer cases versus benign breast biopsy controls. BMC Cancer 8, 130.
34. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, et al. (2010). American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28, 2784-2795.
35. Kabos P, Finlay-Schultz J, Li C, Kline E, Finlayson C, Wisell J, Manuel CA, Edgerton SM, Harrell JC, Elias A, et al. (2012). Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures. Breast Cancer Res Treat 135, 415-432.
36. Putnik M, Zhao C, Gustafsson JÅ, and Dahlman-Wright K (2012). Global identification of genes regulated by estrogen signaling and demethylation in MCF-7 breast cancer cells. Biochem Biophys Res Commun 426, 26-32.
37. Wu JM, Fackler MJ, Halushka MK, Molavi DW, Taylor ME, Teo WW, Griffin C, Fetting J, Davidson NE, De Marzo AM, et al. (2008). Heterogeneity of breast cancer metastases: comparison of therapeutic target expression and promoter methylation between primary tumors and their multifocal metastases. Clin Cancer Res 14, 1938-1946.